Adicet Bio, Inc. Provides Corporate Update and Highlights 2026 Milestones
I'm PortAI, I can summarize articles.
Adicet Bio, Inc. provided a corporate update on January 7, 2026, highlighting significant advancements in its clinical programs and key milestones for the year. Notable achievements include doubling enrollment in the prula-cel Phase 1 program to over 20 patients, FDA alignment for outpatient dosing in lupus trials, and an expected regulatory filing for ADI-212 in prostate cancer in the first half of 2026. The company also extended its cash runway into the second half of 2027 following a $74.8 million equity offering and plans to initiate a pivotal study for prula-cel in the second half of 2026, pending FDA clearance.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments